Please join us for our fourth quarterly call and year end update of 2017 on April 5, 2018 at 4:30pm.
TapImmune President and CEO, Peter Hoang, to present at 2018 The Microcap Conference.
TapImmune President & CEO, Peter Hoang, will be participating in two conferences next week.
TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
Dr. Kenney will continue to manage the Company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.
TapImmune President and CEO, Peter Hoang, to host live webcast on December 7th at 10:45am.
TapImmune President and CEO, Peter Hoang, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference.
TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer
Triple-negative breast cancer is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that.
Peter L. Hoang pens a personal letter to TapImmune’s shareholders.